Literature DB >> 28439936

HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

K Steininger1, A Boyd2, S Dupke3, I Krznaric3, A Carganico3, M Munteanu4, S Neifer5, M Schuetze6, M Obermeier6, K Arasteh7, A Baumgarten3, P Ingiliz3.   

Abstract

Acute hepatitis C virus infection remains a major health concern in human immunodeficiency virus(HIV)-infected men who have sex with men (MSM). New direct-acting antiviral agent (DAA) combination therapy has not yet been approved for the treatment for acute hepatitis C virus(HCV), thereby potentially causing deferral of HCV treatment. Therefore, we aimed to study the course of liver disease after an episode of acute HCV. This study is a retrospective single-centre cohort of HIV-positive MSM with acute HCV infection. Liver fibrosis was estimated by Fibroscan® and Fibrotest® . Liver-related and non-liver-related outcomes were documented. Overall 213 episodes of acute HCV infection in 178 men were documented. Median follow-up for all included patients was 38.7 months. Spontaneous HCV clearance was found in 10.8% of patients, which was significantly associated with older age, lower HCV RNA levels, and higher ALT levels upon initial acute HCV diagnosis. Treatment with interferon-based therapy was initiated in 86.3% of cases, resulting in a sustained virological response(SVR) rate of 70.7%. After 3 years' follow-up, significant liver fibrosis of METAVIR F2 stage or higher was found in 39.4% of patients after first acute HCV diagnosis. Higher age, physician-declared alcoholism, and nonresponse to acute HCV therapy were independently associated with higher fibrosis stages. Ten patients died during the observation period (IR 1.4/100 patient-years) and four during interferon treatment. Significant liver fibrosis is a common finding in HIV-positive MSM following acute HCV infection despite high treatment uptake and cure rates, suggesting the need for close liver disease monitoring particularly if HCV treatment is deferred.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  cirrhosis; fibrosis progression; human immunodeficiency virus/hepatitis C virus coinfection; interferon; spontaneous clearance; sustained virological response

Mesh:

Substances:

Year:  2017        PMID: 28439936     DOI: 10.1111/jvh.12707

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

1.  Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis.

Authors:  Natasha K Martin; Klaus Jansen; Matthias An der Heiden; Christoph Boesecke; Anders Boyd; Knud Schewe; Axel Baumgarten; Thomas Lutz; Stefan Christensen; Alexander Thielen; Stefan Mauss; Jürgen K Rockstroh; Britt Skaathun; Patrick Ingiliz
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

2.  High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients.

Authors:  David Chromy; Mattias Mandorfer; Theresa Bucsics; Philipp Schwabl; Bernhard Scheiner; Caroline Schmidbauer; Maximilian Christopher Aichelburg; Peter Ferenci; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger
Journal:  United European Gastroenterol J       Date:  2019-03-06       Impact factor: 4.623

3.  Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort.

Authors:  Daniela K van Santen; Jannie J van der Helm; Giota Touloumi; Nikos Pantazis; Roberto Muga; Barbara Gunsenheimer-Bartmeyer; M John Gill; Eduard Sanders; Anthony Kelleher; Robert Zangerle; Kholoud Porter; Maria Prins; Ronald B Geskus
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

4.  Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.

Authors:  Lara K Marquez; Patrick Ingiliz; Christoph Boesecke; Ivanka Krznaric; Knud Schewe; Thomas Lutz; Stefan Mauss; Stefan Christensen; Jürgen K Rockstroh; Sonia Jain; Feng He; Joel O Wertheim; Natasha K Martin
Journal:  PLoS One       Date:  2022-05-12       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.